Results 171 to 180 of about 52,849 (269)

The Impact of Monetary Policy on the U.S. Stock Market since the COVID-19 Pandemic

, 2023
Thorbecke W.
europepmc   +1 more source

A study on the influence mechanism of CBDC on monetary policy: An analysis based on e-CNY. [PDF]

PLoS One, 2022
Yang J, Zhou G.
europepmc   +1 more source

Monetary policy responses to COVID-19 in emerging European economies: measuring the QE announcement effects on foreign exchange markets. [PDF]

Empirica (Dordr), 2023
Uz Akdogan I.
europepmc   +1 more source

Monetary policy [PDF]

Intereconomics, 1973
openaire   +2 more sources

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

From theory to practice: Monetary policy transmission and bank risk dynamics. [PDF]

PLoS One
Zhang Z, Clovis J, Moffatt P, Wang W.
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Monetary Policy

, 2007
openaire   +2 more sources

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Does the implementation of economic policies connected to climate change depend on monetary policy mandates and financial stability governance structures? [PDF]

Heliyon
Cheng L, Wu C.
europepmc   +1 more source